ATE262586T1 - Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin - Google Patents

Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin

Info

Publication number
ATE262586T1
ATE262586T1 AT95943342T AT95943342T ATE262586T1 AT E262586 T1 ATE262586 T1 AT E262586T1 AT 95943342 T AT95943342 T AT 95943342T AT 95943342 T AT95943342 T AT 95943342T AT E262586 T1 ATE262586 T1 AT E262586T1
Authority
AT
Austria
Prior art keywords
egf receptor
type iii
mutant egf
fusion junction
junction type
Prior art date
Application number
AT95943342T
Other languages
English (en)
Inventor
Albert J Wong
David K Moscatello
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE262586T1 publication Critical patent/ATE262586T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95943342T 1994-11-28 1995-11-28 Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin ATE262586T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34752094A 1994-11-28 1994-11-28
PCT/US1995/015401 WO1996016988A1 (en) 1994-11-28 1995-11-28 Reagents and processes for targeting mutant epidermal growth factor receptors

Publications (1)

Publication Number Publication Date
ATE262586T1 true ATE262586T1 (de) 2004-04-15

Family

ID=23364052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95943342T ATE262586T1 (de) 1994-11-28 1995-11-28 Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin

Country Status (7)

Country Link
US (1) US6224868B1 (de)
EP (1) EP0796277B1 (de)
JP (2) JP4620808B2 (de)
AT (1) ATE262586T1 (de)
CA (1) CA2206343C (de)
DE (1) DE69532767T2 (de)
WO (1) WO1996016988A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
US5914269A (en) 1997-04-04 1999-06-22 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of epidermal growth factor receptor expression
CA2380631A1 (en) * 1999-07-30 2001-02-08 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Human p53 mutations and a genetic system in yeast for functional indentification of human p53 mutations
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1276771A4 (de) * 2000-03-10 2003-06-04 Thomas Jefferson Univarsity Empfindlicher nachweis von egfr-mutanten und wildtyp durch spezifische elisa-nachweise in jeglicher biologischer probe
US6444465B1 (en) 2000-09-29 2002-09-03 Isis Pharmaceuticals, Inc. Antinsense modulation of Her-1 expression
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US8021658B2 (en) 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US20050175625A1 (en) * 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) * 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US7084246B2 (en) * 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
AU2012268864B2 (en) * 2003-06-27 2016-01-21 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2011265359B9 (en) * 2003-06-27 2014-04-10 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AU2015242981B2 (en) * 2003-06-27 2017-10-19 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
DK1940461T3 (da) * 2005-11-02 2014-03-31 Univ Duke Samtidig kemoterapi og immunterapi
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US9340601B2 (en) * 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
WO2009102493A2 (en) * 2008-02-12 2009-08-20 The Board Of Trustees Of The Leland Stanford Junior University Use of egfrviii to identify and target cancer stem cells
EP2690175B1 (de) * 2008-09-02 2016-12-28 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
SG181628A1 (en) 2009-12-22 2012-07-30 Celldex Therapeutics Inc Vaccine compositions
DK2640842T3 (en) * 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
CN104780938A (zh) 2012-08-02 2015-07-15 小利兰·斯坦福大学托管委员会 用于肿瘤治疗的基于EGFRvIII序列的肽疫苗
WO2015142713A1 (en) * 2014-03-17 2015-09-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for reducing c/ebp homologous protein activity in myeloid-derived suppressor cells
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
CA2968510C (en) 2014-11-25 2020-11-03 Pharmabcine Inc. Novel egfrviii antibody and composition comprising same
CA2982533A1 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same
HK1250662A1 (zh) 2015-04-13 2019-01-11 Aduro Biotech, Inc. 用於治疗癌症的免疫原性融合蛋白
SG11201806597XA (en) * 2016-02-15 2018-09-27 Samsung Life Public Welfare Foundation ANTIBODY AGAINST EGFRvIII AND USE THEREOF
WO2017142294A1 (ko) * 2016-02-15 2017-08-24 사회복지법인 삼성생명공익재단 EGFRvIII에 대한 항체 및 이의 용도
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69025946T2 (de) * 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
JP2690814B2 (ja) * 1991-09-03 1997-12-17 山之内製薬株式会社 ピラゾロトリアゾール誘導体
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
ATE262586T1 (de) * 1994-11-28 2004-04-15 Univ Jefferson Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin

Also Published As

Publication number Publication date
JP2007297398A (ja) 2007-11-15
JP4620808B2 (ja) 2011-01-26
CA2206343C (en) 2009-04-07
EP0796277A1 (de) 1997-09-24
JPH10509878A (ja) 1998-09-29
DE69532767T2 (de) 2004-08-12
WO1996016988A1 (en) 1996-06-06
CA2206343A1 (en) 1996-06-06
DE69532767D1 (en) 2004-04-29
US6224868B1 (en) 2001-05-01
EP0796277A4 (de) 2001-01-24
EP0796277B1 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
DE69532767D1 (en) Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
WO2001098335A3 (en) Transgenic algae for delivering antigens to an animal
MA24638A1 (fr) Vaccin
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
NZ331176A (en) Receptor protein designated 2F1, DNA encoding 2F1, preparation and use thereof
MY125202A (en) Vaccine
IL138075A0 (en) Vaccines, immunotherapeutics and methods for using the same
EP0815125A4 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
EP1245676A4 (de) Humane monoklonale antikörper gegen den tgf-beta ii rezeptor und dessen medizinische verwendung
ATE328068T1 (de) Papillomavirus vakzine
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
BR9809656A (pt) Composição imunopotencializante
BR9912176A (pt) Epìtopos de célula auxiliar t artificial como estimuladores imunes para imunógenos de peptìdeo sintéticos incluindo peptìdeos de lhrh imunogênicos
EE200100549A (et) Meetod fibroosi ravimiseks integriini alfa-4 subühiku antagonistide abil
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
HUP9701586A2 (hu) Javított inaktivált vakcinák
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
SG146662A1 (en) Method
ATE248601T1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
NO984052L (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties